New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

C4T had a productive Type C meeting with the U.S. Food and Drug Administration (FDA) that enabled further refinement of the cemsidomide registrational development plan. By year-end 2025, C4T expects ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

The demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplant procedures, driven by the growing incidence of ...

Propel Health Communications, a 2025 MM+M Agency 100 honoree, hired Christopher Thorn as SVP, creative director and Lauren Schulz as SVP of client services. DiaMedica announced the appointment of ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

Takeda Pharmaceutical Company saw its drug Entyvio (vedolizumab) approved in China by the National Medical Products ...